So I'm Natalie Callandar from the University of Wisconsin, and part of the team that updated data on what's called the iMMagine trial.
This involves a different BCMA CAR-T that uses a binding receptor. That’s different from both Ide-cel and Cilta-cel. The reason is that it’s completely synthetic. The idea is that maybe it is not binding in a way that could lead to additional side effects.
Of course, what we wanted to see with more time is whether the efficacy is still there and if the progression-free survival is looking good. Both of those things are very true.
The response rate is very close to what has been seen with Cilta-cel, which is encouraging—about 96%. The progression-free survival also looks excellent.
But the most important thing, and what everybody was very excited about at this meeting, is that some BCMA-associated CAR-T procedures can be associated with neurotoxicity. This can include things like cranial nerve palsy, where you can get primarily a facial palsy that affects the side of the face or the eye.
More concerning are neurotoxicities that appear later, which can look like Parkinson’s, meaning people may develop movement disorders or balance issues.
The really big news is that so far, in the follow-up, there has not been any signal of early or late neurotoxicity, which is very reassuring.
We’re hoping that this kind of data and update will lead to an approval for Anito-cel sometime this coming year.
If our videos have helped you in any way and you're able to, please consider making a donation to help us continue this important work.
Your gift will go three times as far when we reach $500,000 by the end of the year. Every contribution, big or small, makes a difference, and we're deeply grateful for your support.
HealthTree • December 17, 2025